Analysis

Tempus AI's Strategic Expansion in the Biotech Sector and Its Financial Performance

  • 08/28/2024

Tempus AI's Innovative Approach in Healthcare Technology

  • 08/22/2024
News

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DN.
    11/11/2024

Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript

  • Tempus AI, Inc. (NASDAQ:TEM ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Rachel Vatnsdal – JPMorgan Michael Ryskin – Bank of America Daniel Brennan – TD Cowen Ryan MacDonald – Needham Andrew Brackmann – William Blair Operator Thank you for standing by. My name is Briana, and I will be your conference operator today.
    11/09/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Tempus AI, Inc. Class A Common Stock (TEM) can sell. Click on Rating Page for detail.

The price of Tempus AI, Inc. Class A Common Stock (TEM) is 69.465 and it was updated on 2024-11-12 11:00:32.

Currently Tempus AI, Inc. Class A Common Stock (TEM) is in undervalued.

News
    
News

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, which convenes in Houston, Texas, from November 6-10, 2024. “Presenting our latest research is a vital opportunity to showcase the advancements Tempus is making in harnessing the power of data and AI to drive im.
    Fri, Nov. 08, 2024

Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are already considered candidates for immune checkpoint inhibitor (.
    Thu, Nov. 07, 2024

Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates

  • TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
    Tue, Nov. 05, 2024

Tempus to Report Third Quarter 2024 Financial Results on November 4

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus.
    Sun, Nov. 03, 2024

Tempus: Attempting To Lead The AI Revolution In Healthcare

  • Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. TEM aims to leverage AI and ML and revolutionize healthcare diagnostics, a space which has large gaps and is relatively untapped. Despite an impressive revenue profile and a burgeoning data licensing vertical, TEM remains a long way off profitability and faces high operating cash burn and SG&A expenses.
    Tue, Oct. 29, 2024
More Headlines
News

Tempus to Report Third Quarter 2024 Financial Results on November 7

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast w.
  • 10/24/2024

Tempus Stock Up Following Collaboration Expansion in Oncology R&D

  • TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.
  • 09/30/2024

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts. After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon.
  • 09/26/2024

Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, which convenes in Barcelona, Spain, from September 13-17, 2024. "ESMO provides a great platform to share our recent research and advancements with the global oncology community, foster further collaboration, and drive.
  • 09/13/2024

Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data. olivia, which is currently only available to beta users, leverages generative AI to provide patients and their caregivers persona.
  • 09/12/2024

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  • Cathie Wood bought shares of AMD, DraftKings, and Tempus AI on Tuesday. AMD is growing its data center and AI chips business, but it's struggling badly in other segments.
  • 09/11/2024

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  • Cathie Wood bought shares of Tempus AI, Blade Air Mobility, and Absci on Thursday. Tempus AI was a broken IPO shortly after going public two months ago, but it soared 34% in August.
  • 08/30/2024

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  • Cathie Wood bought shares of DraftKings, Shopify, and Tempus AI on Monday. DraftKings is boosting its revenue guidance, but having to backtrack on a player surcharge isn't a good look.
  • 08/27/2024

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

  • In this article, Seeking Alpha editors highlight 12 ideas published last week focused on stocks with less coverage on our platform. Energy ideas are prevalent in this edition with articles highlighted on uranium development, oil & gas, and clean energy companies. Healthcare-related stocks are in focus as well, with a couple of biotech picks, a skilled nursing facility operator, and a healthcare technology company included.
  • 08/23/2024

Biotech Stock Soars 60% in 2024: Cathie Wood's Bold Investment

  • In just ten days, shares of the mid-cap healthcare stock Tempus AI NASDAQ: TEM have gone from down 4% to up nearly 60% in 2024. Famed investor Cathie Wood recently increased her allocation to the company through the ARK Invest family of funds.
  • 08/23/2024

Why Tempus AI Stock Skyrocketed Nearly 22% Today

  • The recently listed company expanded its shareholding in a biotech. It now owns over 19% of biotech Personalis' common equity.
  • 08/21/2024

Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'

  • Tempus AI provides an end-to-end diagnostic platform connecting clinical, molecular, and image data for physicians and pharmaceutical companies. The company's key competitive advantages include broad data collection, a genomics platform, and intelligent diagnostics, positioning Tempus uniquely in the healthcare technology industry. Recent financial results show 25% year-over-year revenue growth, with Softbank's investment indicating disruptive potential in healthcare diagnostics and precision medicine.
  • 08/21/2024

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

  • BERGEN, Norway , Aug. 21, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update. Highlights, including post period: BGBC016 1L NSCLC STK11m study continues to progress as planned.
  • 08/21/2024

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  • Cathie Wood of Ark Invest bought millions of dollars worth of shares recently. Amazon was a key purchase across most of her funds.
  • 08/20/2024

3 Stocks for the AI Age

  • We all know by now that compound interest is hard to visualize. As early as 1256 AD, storytellers began recording the wheat and chessboard problem.
  • 08/18/2024

Tempus AI Soars To New Highs, Investments From Google And SoftBank Boost Bullish Sentiment

  • Tempus AI Inc. TEM, a cutting-edge healthcare diagnostics company, has been on a tear. The stock established a new high of $47.81 on Thursday.
  • 08/16/2024

7 Growth Stocks to Buy on Corrections for 3X Returns by 2026

  • The S&P 500 index touched highs of 5,670 in July. Over the last one month, the index movement has been volatile with a downward bias.
  • 08/15/2024

7 Growth Stocks That Could 7X in the Next 7 Years

  • The recent market correction is a reminder to investors that it's important to remain grounded even during bull markets. By this, I imply having a balanced portfolio and staying away from overvalued stocks.
  • 08/08/2024

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  • Wood added to her positions in Amazon, Tesla, and Tempus AI on Monday. Amazon has seen its stock fall since posting poorly received results last week, but it's still a leader.
  • 08/06/2024

3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns

  • Global markets are down as fears of an economic downturn triggered a near-term crisis. This is a reminder that corrections can come from most unexpected events.
  • 08/06/2024

3 AI-Powered Healthcare Stocks Transforming Medicine

  • AI healthcare stocks can potentially revolutionize patient care as we know it. The groundbreaking technology is expected to have a pervasive impact on the investment world, with its most profound anticipated transformations in healthcare.
  • 08/02/2024

7 New Growth Stock Listings That Can Be Long-Term Wealth Creators

  • The initial public offering (IPO) and the subsequent listing is one of the best times to buy new growth stocks. The markets are still in a phase of understanding the business potential and there is limited analyst coverage.
  • 08/02/2024

3 AI-in-Healthcare Stocks to Buy for Outsized Returns

  • Across industries, companies will need to adopt AI for growth and survival. A PricewaterhouseCoopers indicates that by 2030, AI could contribute up to $15.7 trillion to the global economy.
  • 07/29/2024

7 Growth Stocks That Can Create Millionaires by 2030

  • In June 2010, Tesla (NASDAQ: TSLA ) was listed with a market valuation of $2.23 billion. Currently, the EV maker commands a market valuation of $785 billion.
  • 07/26/2024

7 Millionaire-Making Growth Stocks to Buy and Forget

  • Before entering the markets, investors need to clearly define their objective. If the idea is to take low-risk and beat inflation, it makes sense to go overweight on blue-chip stocks trading at attractive valuations.
  • 07/18/2024

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  • Shopify stock is down, but the e-commerce software platform remains a dominant player. Oklo, a recent IPO backed by Sam Altman, aims to provide clean and affordable energy.
  • 07/18/2024

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  • Cathie Wood bought shares of Shopify, Blade Air Mobility, and Tempus AI on Monday. Shopify and Blade Air are trading lower in 2024.
  • 07/16/2024

3 Under-the-Radar IPO Stocks to Buy Before They Double

  • With the S&P 500 index trading near all-time highs, the initial public offering market has been robust. It's also not uncommon that quality IPO stocks remain under-the-radar for a while before surging higher as it catches analyst and investor attention.
  • 07/15/2024

Tempus AI Has Massive Market Opportunity For This Healthcare Technology, Bullish Analyst Says

  • William Blair initiated coverage on Tempus AI, Inc TEM, citing the company's ‘differentiated approach and business model.'
  • 07/09/2024

Why Wall Street Is Bullish on Healthcare Tech Stock Tempus AI

  • Several analysts kicked off coverage of Tempus AI (TEM) with bullish comments, anticipating gains from the biotech company's applications of artificial intelligence (AI) to healthcare.
  • 07/09/2024

AI-boosted medical diagnostics firm Tempus AI given 'buy' rating

  • Tempus AI (NASDAQ:TEM), a provider of AI-enabled precision medicine, has been initiated with a 'buy' rating by Bank of America, which likes how the company combines a patient's molecular, clinical and other data to provide a new level of medical diagnostics.  There are other companies that provide similar molecular diagnostics – Guardant Health, Foundation Medicine, NeoGenomics (NASDAQ:NEO) for three – Tempus differs from most of them by adding layers of additional patient information such as MRI imaging data, patient records, as well as AI techniques such as neural networks, deep learning, and large language models.
  • 07/09/2024

TD Cowen's Dan Brennan on why he's bullish on Tempus

  • Dan Brennan, senior analyst at TD Cowen, joins CNBC's 'The Exchange' to discuss his price target on Tempus, AI in diagnostics, and more.
  • 07/09/2024

Buy this healthcare company's stock because it's an AI play, analysts say

  • A number of Wall Street analysts on Tuesday made bullish calls on the shares of a newly public healthcare company that uses artificial intelligence to differentiate itself in the cancer-diagnostics space.
  • 07/09/2024

Wall Street analysts bullish on genetic testing firm Tempus AI

  • Wall Street brokerages started covering SoftBank Group-backed Tempus AI on a bullish note on Tuesday, betting that the company's AI-powered library of clinical and molecular data could lead to more powerful diagnostic and test kits.
  • 07/09/2024

IPO Watch: 3 New Stocks Worth a Strong Look

  • The market for initial public offerings (IPOs), featuring promising new IPOs, has rebounded strongly in 2024, with the number of offerings surpassing last year's total by 40%. The combined valuation of this year's IPOs has more than doubled compared to the previous year, sparking speculation about future public offerings.
  • 07/05/2024

SoftBank Group launches AI healthcare joint venture with Tempus AI

  • Japanese technology investor SoftBank Group has launched a joint venture with Tempus AI that aims to analyse personal medical data with artificial intelligence (AI) to come up with treatment recommendations.
  • 06/27/2024

Revere Payments Named BigCommerce Preferred Technology Partner

  • PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Revere Payments helps fast-growing BigCommerce customers streamline payment processes and improve transaction security and enhance customer experience.
  • 06/26/2024

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF). This is the first FDA clearance for an AF indication in the category known as “cardiovascular machine learning-based notification software” and paves.
  • 06/26/2024

Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotechnology company focused on providing a brighter future for patients through the development of novel pharmaceuticals and technologies. As part of this collaboration, Tempus will develop and investigate AI-based medical device software to detect patients at risk of having undiagnosed pulmonary hyper.
  • 06/25/2024

Google Invested in This Hot New Artificial Intelligence (AI) Stock. Should You?

  • Tempus AI conducted its IPO last week. The healthcare AI company has financial backing from Google.
  • 06/19/2024

Tempus IPO: Stock price watched today as AI health-tech company starts Nasdaq trading

  • Nothing is hotter in tech right now than artificial intelligence. No wonder then that many AI companies see 2024 as the year to go public.
  • 06/16/2024

U.S. IPO Weekly Recap: Precision Medicine IPO Tempus AI Posts A Modest Gain In Its Debut

  • One large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading - Tempus AI, Telix Pharmaceuticals, Centurion Acquisition, and Perceptive Capital Solutions, respectively. One nanocap is currently scheduled to list in the week ahead, although some other small issuers may join the calendar throughout the week - Nova Minerals. Street research is expected for one company in the week ahead, and lock-up periods will be expiring for one company.
  • 06/15/2024

Tempus AI: Healthcare AI Play Faces Some Challenges From The Start

  • Tempus AI, Inc, aims to revolutionize precision medicine with AI technology and healthcare data. The promise looks good, as the revenue base is substantial, but unfortunately the same applies to the losses incurred. With revenue growth slowing down dramatically and operating leverage coming to a standstill, I am leaning cautious about Tempus here.
  • 06/14/2024

Tempus AI Surges in Nasdaq Debut Following IPO

  • Shares of healthcare technology firm Tempus AI surged Friday as they began trading on the Nasdaq.
  • 06/14/2024

Tempus AI shares soar in Nasdaq debut

  • SoftBank Group-backed Tempus AI shares surged over 15% after its Nasdaq debut Friday, valuing the AI-driven genetic testing company at around $6.6 billion. The stock opened at $40 per share and rose to trade around $42.30 by midday, compared to the initial public offering (IPO) price of $37.
  • 06/14/2024

Tempus AI shares jump 8% in Nasdaq debut

  • Shares of SoftBank Group-backed Tempus AI rose 8.1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6.6 billion.
  • 06/14/2024

TEM Stock IPO: 7 Things to Know as Tempus AI Starts Trading Today

  • One of the season's most highly anticipated initial public offerings (IPOs) is taking place today. Tempus AI (NASDAQ: TEM ), a company bringing artificial intelligence (AI) to the data processing space, begins trading today after weeks of anticipation.
  • 06/14/2024

Tempus AI CEO Eric Lefkofsky on going public: It's been an incredible journey

  • Tempus AI founder and CEO Eric Lefkofsky joins 'Squawk Box' to discuss taking the company public on Nasdaq later today, the origin of the company,
  • 06/14/2024

Tempus AI announces pricing of US IPO

  • SoftBank Group-backed Tempus AI announced on Thursday the pricing of its initial public offering of 11.1 million ordinary shares at a price of $37 apiece.
  • 06/13/2024

Tempus Announces Pricing of Initial Public Offering

  • CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37.00 per share. All of the shares of Class A common stock are being offered by Tempus. The gross proceeds to Tempus from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Tempus, are expected to be $410.7 million. In addition, Tempus has granted t.
  • 06/13/2024

TEM Stock IPO: When Does Tempus AI Go Public? What Is the Tempus AI IPO Price Range?

  • Tempus AI stock is preparing for an initial public offering ( IPO ) and we have all of the details that traders need to know about before it gets here. Let's get into all of the latest Tempus AI IPO details below ahead of its potential listing this week!
  • 06/10/2024

Healthcare-technology company Tempus AI looks to raise $400 million in IPO

  • Tempus AI Inc. is about to give investors a way to play the intersection of medicine and artificial intelligence.
  • 06/05/2024

Tempus AI seeks up to $6.1 bln valuation in US IPO

  • Tempus AI is targeting a valuation of up to $6.10 billion in its initial public offering in the United States, the genetics testing company said on Wednesday.
  • 06/05/2024

Billionaire Groupon founder Lefkofsky is back with another IPO: AI healthtech Tempus

  • Eric Lefkofsky knows the public listing rodeo well and is about to enter it for a fourth time. The serial entrepreneur, whose net worth is estimated at nearly $4 billion, has already taken three businesses he's founded public.
  • 05/30/2024

U.S. IPO Weekly Recap: Specialty Insurer Bowhead Sole IPO To Debut As More Names Join The Pipeline

  • Specialty property & casualty insurer Bowhead Specialty Holdings priced its upsized IPO at the top of the range to raise $128 million at a $551 million market cap. Three IPOs submitted initial filings this past week. The May IPO market is expected to end on a quiet note, with no IPOs currently scheduled for the short Memorial Day week.
  • 05/27/2024
Unlock
TEM Ratings Summary
TEM Quant Ranking